Who Paid My Doc
Taylor Rives
Gynecologic Oncology Gainesville, GA Medical Doctor
NPI 1649762097 CMS profile 4950832
743 Spring St Ne, Gainesville, GA 30501
General payments
$1,685
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Taylor Rives of Gainesville, GA is reported in the CMS Open Payments database as having received $1,685 across 16 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 51st percentile of Gynecologic Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $199 | 6 | |
| 2024 | General | $1,058 | 3 | |
| 2023 | General | $107 | 1 | |
| 2022 | General | $61 | 2 | |
| 2019 | General | $260 | 4 |
Beside peers
- Taylor Rives
- Gynecologic Oncology median
- Middle half of Gynecologic Oncology
- National median
In program year 2025, general payments to Taylor Rives were reported at $199. Among 1,179 Gynecologic Oncology profiles paid that year, the median was $305 and the middle half received between $111 and $1,499.
Show as a table
| Year | Taylor Rives | Gynecologic Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $260 | $287 | $113–$1,548 | $163 |
| 2020 | $0 | $223 | $59–$2,164 | $114 |
| 2021 | $0 | $193 | $68–$1,139 | $132 |
| 2022 | $61 | $252 | $90–$1,151 | $149 |
| 2023 | $107 | $281 | $102–$1,419 | $160 |
| 2024 | $1,058 | $308 | $108–$1,502 | $164 |
| 2025 | $199 | $305 | $111–$1,499 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 5 drugsPart D claims
132
Drug cost
$14,858
Branded share of claims
16.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 22 | $12,867 | |
| Megestrol Acetate | Generic | 19 | $1,253 | |
| Oxycodone Hcl | Generic | 39 | $402 | |
| Gabapentin | Generic | 41 | $272 | |
| Omeprazole | Generic | 11 | $66 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Records
16 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Gynecologic Oncology in Georgia
Related records
Gynecologic Oncology in Georgia
Practitioners in the same specialty and state, ranked by reported value.
All Gynecologic Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Georgia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.